Your session is about to expire
← Back to Search
Nicotinamide for Skin Cancer Prevention (SPRINTR-Pilot Trial)
SPRINTR-Pilot Trial Summary
This trial will test if a drug called nicotinamide can help prevent skin cancer in people who have had organ transplants. If it is successful, it will become a larger trial.
- Non-melanoma Skin Cancer
- Squamous Cell Carcinoma
- Basal Cell Carcinoma
SPRINTR-Pilot Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 46 Patients • NCT03061474SPRINTR-Pilot Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have used nicotinamide or niacin (at least 250 mg daily) in the last 12 weeks.You have used any treatment for actinic keratoses on your skin in the last 12 weeks.You have a genetic condition that increases your risk of developing skin cancer.You have had a type of cancer in your organs or blood, or certain types of skin cancer, within the past few years.You are currently taking carbamazepine or primidone medication.
- Group 1: Nicotinamide
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What purpose is Nicotinamide most regularly utilized for?
"Nicotinamide is often employed to address nutrient deficiencies, nutritional supplements, and dietary therapies."
How many participants are registered for this research project?
"This investigation is not accepting participants currently; it was initially posted on December 3rd 2018 and most recently edited on February 9th 2022. However, if you are seeking other trials, there are presently 2710 studies recruiting patients suffering from carcinoma squamous cell as well as 12 clinical investigations needing participants with Nicotinamide related illnesses."
Has Nicotinamide been given the greenlight by the Food & Drug Administration?
"Since this is a Phase 2 trial, there are some safety data but no efficacy information available. Therefore, the team at Power gave Nicotinamide an intermediate rating of two on their scale of 1-3."
Is enrollment currently available to those interested in participating?
"Per the information presented on clinicaltrials.gov, this trial is not presently accepting participants as it has not been updated since February 9th 2022. However, there are 2,722 other medical studies actively enrolling patients at present time."
Share this study with friends
Copy Link
Messenger